Key Takeaways From Twist Bioscience Analyst Ratings
Analysts' ratings for Twist Bioscience (NASDAQ:TWST) over the last quarter vary from bullish to bearish, as provided by 8 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 6 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 4 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated Twist Bioscience and provided 12-month price targets. The average target is $50.12, accompanied by a high estimate of $65.00 and a low estimate of $40.00. Surpassing the previous average price target of $44.71, the current average has increased by 12.1%.
Interpreting Analyst Ratings: A Closer Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive Twist Bioscience. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luke Sergott | Barclays | Raises | Overweight | $60.00 | $45.00 |
| Steven Mah | TD Cowen | Raises | Buy | $65.00 | $55.00 |
| Subbu Nambi | Guggenheim | Announces | Buy | $53.00 | - |
| Sung Ji Nam | Scotiabank | Raises | Sector Outperform | $48.00 | $43.00 |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $50.00 | $46.00 |
| Luke Sergott | Barclays | Raises | Overweight | $45.00 | $40.00 |
| Catherine Ramsey | Baird | Raises | Outperform | $40.00 | $39.00 |
| Luke Sergott | Barclays | Lowers | Overweight | $40.00 | $45.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Twist Bioscience. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Twist Bioscience compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Twist Bioscience's stock. This analysis reveals shifts in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Twist Bioscience's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Twist Bioscience analyst ratings.
Discovering Twist Bioscience: A Closer Look
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of its revenue from the United States.
Unraveling the Financial Story of Twist Bioscience
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Twist Bioscience's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 25.13%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Twist Bioscience's net margin excels beyond industry benchmarks, reaching -60.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Twist Bioscience's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.91% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -6.34%, the company showcases effective utilization of assets.
Debt Management: Twist Bioscience's debt-to-equity ratio is below the industry average at 0.16, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.